&w=3840&q=100)
Institutional buyers drive demand for Anthem Biosciences IPO; GMP up 26%
Among the individual categories, NIIs have oversubscribed the category reserved for them by 27.08 times, followed by QIBs at 11.86 times, and retail investors at 3.80 imes.
Anthem Biosciences IPO grey market premium (GMP) today
The favourable sentiments were seen in the grey markets too, where the company's unlisted shares were exchanging hands at around ₹720 apiece, reflecting a grey market premium (GMP) of ₹150 per share or approximately 26.32 per cent above the upper end of the IPO price band of ₹570 apiece, according to the sources tracking grey market activities.
Anthem Biosciences IPO review
Analysts at Anand Rathi Research have assigned a subscribe rating to the issue, citing the company's potential to continue to grow its revenue and profitability ratios compared to its peers. Those at SBI Securities have recommended the investors to subscribe to the public issue for the long-term perspective, citing that the IPO is fairly priced while comparing with peers, along with a superior return and margin profile.
Anthem Biosciences IPO details
The ₹3,395.00 crore public issue of Anthem Biosciences comprises an entirely offer for sale (OFS) with promoters and shareholders divesting 59.6 million equity shares. The public issue is being offered in a price band of ₹540-570 per share, with a lot size of 26 shares. A retail investor can bid for a minimum of 1 lot or 26 and in multiples thereof, with a minimum investment of ₹14,820.
As the subscription window closed today, the basis of allotment of Anthem Biosciences IPO shares is expected to be finalised on July 17, with shares credited to successful applicants' demat accounts on July 18.
Anthem Biosciences shares are scheduled to list on the NSE and BSE tentatively on July 21, 2025.
Kfin Technologies is acting as the registrar to the issue, while JM Financial is serving as the sole book-running lead manager.
About Anthem Biosciences
Anthem Biosciences is an innovation-led CRDMO (Contract Research Development and Manufacturing Organization) in India, offering end-to-end services across drug discovery, development, and manufacturing for both New Chemical Entity (NCE) and New Biological Entity (NBE). The company is among a select group of Indian players with integrated capabilities spanning New Chemical Entities (NCEs) and New Biological Entities (NBEs) across the drug discovery, development, and commercial manufacturing value chain.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
7 minutes ago
- Business Standard
This MFI lender's stock soars 7% even as Q1 profit plunges; Here's why
Shares of CreditAccess Grameen rose over 7 per cent on Wednesday even after the company reported an 85 per cent year-on-year (Y-o-Y) to ₹60.2 crore for the quarter ended June 2025 (Q1FY26). The micro finance lender's stock rose as much as 7.05 per cent during the day to ₹1,370 per share. The stock pared gains to trade 5.3 per cent higher at ₹1,347 apiece, compared to a 0.43 per cent advance in Nifty 50 as of 1:10 PM. Shares of the company have been range-bound since July, and at day's high, the stock was at the highest level since July 2, 2024. The counter has risen 52 per cent this year, compared to a 6.2 per cent advance in the benchmark Nifty 50. CreditAccess Grameen has a total market capitalisation of ₹21,496.25 crore, according to BSE data. CreditAccess Grameen Q1 results The microfinance lender's net profit declined 85 per cent Y-o-Y primarily to ₹60.2 crore contraction in net interest income and higher provisioning. Sequentially, the net profit rose 27.5 per cent from Rs 47.2 crore in the quarter ended March 2025 (Q4FY25). The lender's net interest income (NII) declined 1.6 per cent to ₹937 crore. Sequentially, NII grew 7 per cent from ₹876.1 crore in Q4FY25. Its net interest margin (NIM) dropped to 12.8 per cent in Q1FY26 from 13.0 per cent in Q1FY25. However, it improved from 12.7 per cent in Q4FY25. The company's gross non-performing assets (NPAs) rose sharply to 4.70 per cent as of June 2025, up from 1.46 per cent a year ago. It, however, declined from 4.76 per cent at the end of March 2025. Analysts bullish on CreditAccess Grameen While the microfinance industry (MFI) is still navigating stress, JM Financial believes CreditAccess Grameen is best positioned to recover early. This is due to its strong stress recognition framework, along with an accelerated write-off policy and high expected credit loss coverage. Management expects elevated credit costs to persist in Q2FY25, before moderating to 3-3.5 per cent in the second half of FY25. FY26 guidance for loan growth and return on equity (RoE) has been maintained at 14-18 per cent and 11.8-13.3 per cent, respectively, with stronger momentum expected in the second half, particularly from the retail finance book. JM Financial expects around 15 per cent assets under management CAGR over FY25-27. Given the improving outlook, the brokerage has upgraded the stock to 'Buy' and revised the target price to ₹1,475. Analysts at Motilal Oswal said that the lender has successfully navigated a period of industry-wide challenges, demonstrating remarkable resilience and a return to normal operational efficiency. The company will continue to prioritise balance sheet normalisation through accelerated write-offs and prudent provisioning, it said.
&w=3840&q=100)
Business Standard
7 minutes ago
- Business Standard
Concord Biotech rises 2% on incorporating its arm for marketing and sales
Concord Biotech shares rose 2.3 per cent, logging an intraday high at ₹1941.25 per share on the BSE. At 1:22 PM, Concord Biotech share price was trading 1.72 per cent higher at ₹1,930 per share on BSE. In comparison, the BSE Sensex rose 0.43 per cent to 82,544.23. The market capitalisation of the company stood at ₹20,190.93 crore. The 52-week high of the company stood at ₹2,658 per share, and the 52-week low was at ₹1,370.05. Why were Concord Biotech shares buzzing in trade? The buying on the counter came after the company incorporated its subsidiary Concord Lifegen, with an objective to carry out marketing, sales, and distribution of pharmaceutical products. The total cost of acquisition is worth ₹1,00,000. "We are pleased to announce incorporation of Concord's Wholly Owned subsidiary company, namely, 'Concord Lifegen Limited' with objective to carry out marketing, sales, and distribution of pharmaceutical products," the filing read. Its primary objectives include executing targeted sales strategies, ensuring regulatory compliance across domestic and international markets, handling logistics and customer support, and maintaining transparent reporting to the holding company, according to the filing. The authorised share capital (as on July 22, 2025) of Concord Lifegen is ₹1,00,000 divided into 10,000 equity shares of ₹10 each issued share capital (as on July 22, 2025). That apart, in Q4, the company's profit climbed 47.8 per cent year-on-year (Y-o-Y) to ₹140 crore in the March quarter of FY25, from ₹95 crore in the March quarter of FY24. Concord Biotech's revenue from operations surged 34.8 per cent Y-o-Y to ₹429.9 crore in Q4FY25, from ₹319 crore in the same quarter a year ago. About Concord Biotech Concord Biotech is a research-driven biopharmaceutical company specialising in the production of Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Initially a single-product entity, Concord has evolved into a comprehensive solutions provider, offering a broad range of products across various therapeutic segments. The company has established a global presence, distributing its products in over 70 countries, including key markets like the USA, Europe, Japan, and Latin America, while also maintaining a major footprint in India.
&w=3840&q=100)
Business Standard
7 minutes ago
- Business Standard
Monarch Surveyors IPO booked 37x; GMP up 68%; check who is driving demand
Monarch Surveyors IPO comprises an entirely fresh issue of 3.75 million equity shares estimated to be worth ₹93.75 crore. The public offering is available at a price band of ₹237-250 per share. SI Reporter New Delhi Monarch Surveyors IPO Day 2 subscription status: Retail investors were leading the demand for the initial public offering of Monarch Surveyors & Engineering Consultants (Monarch Surveyors IPO) on the second day of its subscription period. The demand for the public issue was also strong among the institutional investors, as the public issue has been oversubscribed by 37.20 times till around 1:20 PM on Wednesday, July 23, 2025. The BSE data shows that the retail investors have placed the highest bids by oversubscribing the category reserved for them by 58.75 times, followed by non-institutional investors (NIIs) at 34.46 times and qualified institutional buyers (QIBs) at 2.27 times. Monarch Surveyors IPO details Monarch Surveyors IPO comprises an entirely fresh issue of 3.75 million equity shares estimated to be worth ₹93.75 crore. The public offering is available at a price band of ₹237–250 per share, and a lot size of 600 shares. The investors can bid for a minimum of 1,200 shares and in multiples of 600 shares thereafter, and would require a minimum of ₹3,00,000 to bid for 2 lots or 1,200 shares of Monarch Surveyors IPO. The company intends to use the net proceeds from the public issue for funding the capital expenditure requirement for purchase of machinery, as well as for funding working capital requirements of the company. The company will further use the proceeds for general corporate purposes. Monarch Surveyors IPO grey market premium (GMP) The unlisted shares of the company continued to trade at a solid premium in the grey markets on Wednesday. Monarch Surveyors shares were trading at around ₹420 per share, reflecting a grey market premium (GMP) of ₹170 or 68 per cent over the upper end of the issue price, according to sources tracking unofficial market activities. Monarch Surveyors IPO allotment date, listing date The three-day subscription window to bid for the Monarch Surveyors IPO is set to conclude on July 24, 2025. Following the closure of the subscription window, the basis of allotment of Monarch Surveyors is set to take place on July 25. The company's shares will be credited into demat accounts tentatively by July 28. About Monarch Surveyors Founded in 1999, Monarch Surveyors & Engineering Consultants offer end-to-end infrastructure consultancy services. The company operates in sectors such as transportation, urban planning, environment, and water. Monarch offers services including high-precision engineering surveys, feasibility studies, and project management. The company has worked with Indian government institutions, road authorities, and private entities. Monarch also has a presence in Sri Lanka and Bhutan, delivering data-driven engineering solutions. The company's services span the entire lifecycle of infrastructure projects, from concept to commissioning. Monarch's expertise includes surveying, design services, and technical supervision for various civil engineering sectors.
